Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company's proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for chronic spinal cord injury (SCI). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product.

Driven by more than 20 years of pioneering research and innovation, StemCells, Inc. is the undisputed leader in human neural stem cell research and development. As the first ever to conduct a U.S. clinical trial with human neural stem cells, StemCells is the only company, to date, with established human safety and preliminary efficacy data for these cells. The Company's comprehensive patent portfolio includes seminal technology in cell biology, with neural stem cell patents covering compositions of matter, methods of manufacture and methods of use. Credited with significant breakthroughs in the field, the StemCells team includes internationally renowned experts in stem cell biology, biotechnology, regenerative medicine and cGMP manufacturing.

Learn more about What Sets Us Apart.

Primary IR Contact

Greg Schiffman
CFO
Stem Cells, Inc.
Phone: (510) 456-4128
Fax: (510) 456-4001
E-mail: irpr@stemcellsinc.com

Stock Performance

STEM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	**$6.40**
Change (%)	▼ 0.27 (4.05%)
Volume	70,704
52 Week Low	$2.97
Market Cap	$0
Rolling EPS	-18.18
PE Ratio	N/A
Shares Outstanding	0

Data as of 12/30/16 4:00 p.m. ET

Chart is not available for this symbol

Recent Headlines & Events

10/27/16
StemCells, Inc. Encourages Stockholders to Return Proxies Approving the Microbot Merger by November 14, 2016

08/16/16
StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger

05/31/16
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation:

Sell *Strong Buy*

EPS Trend				
		Current	30 Days Ago	90 Days Ago
QTR				
QTR				
QTR				
QTR				
FY				
FY				

SEC Filings

Year Filter

All Years

Filing Date	Form
03/30/17	8-K
03/21/17	10-K
03/15/17	8-K
02/24/17	8-K

Corporate Governance

Ken Stratton President and General Counsel

Ownership Summary

Shareholders				
	Holders	Value ($MM)	% O/S	Shares
Institution	53	151.94	89.7	24,431,166
Mutual Fund	11	.35	0.3	71,876
Insider *	15	445.34	71.2	19,414,066

**Insider values reflect direct beneficial ownership.*

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Bornstein (Yoseph)	5,305,409	19.5	5,305,409	12/27/16
Berkson (Avram)	4,307,003	15.8	4,307,003	12/27/16
Technion Research & Development Foundation Ltd (TRDF)	3,555,339	13.1	3,555,339	12/27/16
Lewkowicz (Leon)	3,149,438	11.6	70,496	01/04/17
MEDX Ventures Group LLC	2,652,704	9.7	2,652,704	12/27/16
GreenBlock Capital, L.L.C.	1,950,660	7.2	1,950,660	11/29/16
Shoham (Moshe)	1,842,090	6.8	1,842,090	12/27/16
Alpha Capital Aktiengesellschaft	1,299,476	4.8	1,294,846	11/29/16
Lane Ventures, Inc	216,739	0.8	216,739	11/28/16
BlackRock Institutional Trust Company, N.A.	59,300	0.2	5,265	12/31/16

Powered By EDGAR Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed